If you have been reading about DAC group and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
authorities blocked Caribbean routes in the 1990s, making Mexico, and especially Tamaulipas, a key corridor for drug smuggling. García Ábrego's organizational structure, reliant on corrupting government and police officials, solidified the Gulf Cartel as one of Mexico's most influential criminal organizations, laying the groundwork for its later expansion. His arrest in 1996 marked a turning point, creating a power vacuum that would be filled by Osiel Cárdenas Guillén. Osiel Cárdenas Guillén, who took over the Gulf Cartel after García Ábrego's capture, revolutionized drug trafficking by introducing a paramilitary approach with the creation of Los Zetas in 1999, a group initially composed of elite former Mexican military personnel. This armed wing not only protected the cartel's operations but also expanded its activities to include kidnappings, extortion, and territorial control, marking an escalation in criminal violence. Under his leadership, the cartel intensified cocaine trafficking to U.S. cities such as Houston and Atlanta, generating millions of dollars, as evidenced by records showing profits of 41 million dollars in just three and a half months from shipments to Atlanta. Direct confrontations with authorities and rivals, such as the Sinaloa Cartel over control of Nuevo Laredo, heightened tensions that set the stage for the war on drug trafficking launched in 2006 by President Felipe Calderón.
== Degradation == Modulation of the effects of ANP is achieved through gradual degradation of the peptide by the enzyme neutral endopeptidase (NEP). Recently, NEP inhibitors have been developed, such as Sacubitril and Sacubitril/valsartan. They may be clinically useful in treating patients in heart failure with reduced ejection fraction .
== Treatment == Treatment for Ullrich congenital muscular dystrophy can consist of physical therapy and regular stretching to prevent and reduce contractures. Respiratory support may be needed at some point by the affected individual. Non-invasive ventilation (NIV), typically in the form of bilevel positive airway pressure (BiPAP), is the most commonly used form of respiratory support, with ventilation via a tracheostomy used in some cases. While primary cardiomyopathy is not a typical feature of this type of CMD, chronic respiratory insufficiency can lead to secondary right heart strain, which NIV also helps to prevent.
Sources: en.wikipedia.org
== January 25, 1982 (Monday) == In a speech in Asmara, Ethiopia's President Mengistu Haile Mariam announced his "Red Star Campaign", a military operation to destroy the Eritrean People's Liberation Front and the Tigray People's Liberation Front secessionist groups in Eritrea Province. The campaign would begin on February 15, 1982, and last for almost five months, until July 5, with at least 10,000 Ethiopian and 4,000 Eritrean soldiers killed. Propaganda Due (P2), the controversial Italian Masonic lodge, was formally dissolved after 105 years of operation. The Amol uprising, an unsuccessful rebellion by Siamak Zaim of the League of Iranian Communists, was launched against the Islamic Republic government in Iran's Mazandaran province. The R. E. Ginna Nuclear Power Plant near Ontario, New York in the U.S. sustained a nuclear accident when a tube on a steam generator ruptured and radioactive steam was released for 93 minutes before the problem was fixed. Born: Heather Hardy, enshrinee in the International Women's Boxing Hall of Fame as world female featherweight champion of the World Boxing Organization from 2018 to 2019; in Brooklyn, New York City Died: Mikhail Suslov, 79, Deputy General Secretary of the Soviet Communist Party and the Party's second only to General Secretary and President Leonid Brezhnev. William Russel Huber, 79, U.S. Navy sailor and recipient of the Medal of Honor Mildred Christman, 86, American rodeo bronco riding champion, trick rider, and actress
== Evolutionary origins == Synovial joints have been found in the earliest jawed vertebrates (gnathostomes) 400 million years ago during the Silurian and Devonian. This finding overturns an earlier view that these joints first evolved in early tetrapods for terrestrial locomotion. Comparative studies find that synovial joints are present in all major groups of jawed vertebrates, including cartilaginous fishes (sharks, skates, and rays), bony fishes, and tetrapods. They are, however, absent in jawless vertebrates such as lampreys and hagfish. Cartilaginous fishes have true synovial joints with clear synovial cavities, articular cartilage lined by flattened chondrocytes, and express key developmental signaling molecules including growth differentiation factor-5 (Gdf5) and β-catenin, and require muscle contraction for proper joint cavitation. In contrast, cyclostomes have joints filled with tissue rather than fluid-filled cavities, with proteoglycans uniformly distributed across cartilages. Fossil evidence finds jawless osteostracans had pectoral fin connections filled with canals incompatible with fluid-filled joint cavities, while early jawed placoderms have reciprocally articulating surfaces separated by joint cavities. Synovial joints, it has been suggested, arose due to the high mechanical loads associated with predation and feeding and, as a result, allowed for the evolution of the complex skeletons of modern jawed vertebrates.
== Presentation == MFS usually afflicts individuals in their fifth to seventh decades of life although uncommon cases occur in adults outside of this age range In one large study, MFS was diagnosed in individuals 21 to 96 years old (median age 66 years). Most studies have diagnosed MFS slightly more often in men than women but one large study conducted in France found it to be 50% more common in men. Individuals with MFS present with a tumor located in an extremity (77% of cases, usually in the lower extremity), trunk (12% of cases), and head and neck areas (3% of cases). Rarely, these tumors have presented in the breast, heart, paratesticular region (i.e. area inside the scrotum including the epididymis the spermatic cord along with its coverings), eye, bone, liver, or multiple sites concurrently. Primary tumors presenting in the abdominal cavity, retroperitoneum, or pelvis have been diagnosed as MFS but larger studies indicate that these tumors are far more likely to be dedifferentiated liposarcomas. MFS tumors usually develop as painless, slowly enlarging masses in a muscle, skin (usually below the fascia i.e. a sheet of connective tissue, primarily collagen, running beneath the skin), or one of the non-cutaneous areas described above. In one study of 69 FBS cases 36 were <5 cm, 23 were between 5 and 10 cm, and 19 were > 10 cm in diameter with the largest tumor being 27 cm. MFS tumors often infiltrate along vascular and fascial planes, are incompletely removed at surgery, and consequently recur at the surgical site.
=== Acquired === (G72.0 - G72.2) External substance induced myopathy (G72.0) Drug-induced myopathy Glucocorticoid myopathy is caused by this class of steroids increasing the breakdown of the muscle proteins leading to muscle atrophy. (G72.1) Alcoholic myopathy (G72.2) Myopathy due to other toxic agents, including atypical myopathy in horses caused by toxins in sycamore seeds and seedlings. (M33.0-M33.1) Dermatomyositis produces muscle weakness and skin changes. The skin rash is reddish and most commonly occurs on the face, especially around the eyes, and over the knuckles and elbows. Ragged nail folds with visible capillaries can be present. It can often be treated by drugs like corticosteroids or immunosuppressants. (M33.2) Polymyositis produces muscle weakness. It can often be treated by drugs like corticosteroids or immunosuppressants. Inclusion body myositis is a slowly progressive disease that produces weakness of hand grip and straightening of the knees. No effective treatment is known. (M60.9) Benign acute childhood myositis (M61) Myositis ossificans (M62.89) Rhabdomyolysis and (R82.1) myoglobinurias The Food and Drug Administration is recommending that physicians restrict prescribing high-dose simvastatin (Zocor, Merck) to patients, given an increased risk of muscle damage. The FDA drug safety communication stated that physicians should limit using the 80-mg dose unless the patient has already been taking the drug for 12 months and there is no evidence of myopathy.
Sources: en.wikipedia.org
== History == In 1980 Ferguson-Miller et al. at Michigan State developed n-dodecyl-β-D-maltopyranoside (DDM) as part of a successful effort to purify an active, stable, monodisperse form of cytochrome c oxidase. Maltosides have been used extensively to stabilize membrane proteins for biophysical and structural studies.
== Structure == Threonine has R, S stereochemistry at carbons 2 and 3 for the naturally occurring stereoisomer and S, R stereochemistry for its enantiomer. Allothreonine has S, S stereochemistry at carbons 2 and 3 in the natural stereoisomer, but R, R in the very rare enantiomer.
Within the field of supramolecular polymerization, Schmatloch et al. used automated synthesis to create main-chain supramolecular coordination polymers, reacting bis(2,2′:6′,2″-terpyridine)-functionalized poly(ethylene oxide) with various metal(II) acetates. From this, it was revealed that classical laboratory approaches could be transferred to automatic synthesis, optimizing the processes to increase efficiency and aid with reproducibility.
The following table illustrates variability in reference ranges of serum prolactin between some commonly used assay methods (as of 2008), using a control group of healthy health care professionals (53 males, age 20–64 years, median 28 years; 97 females, age 19–59 years, median 29 years) in Essex, England: An example of the use of the above table is, if using the Centaur assay to estimate prolactin values in μg/L for females, the mean is 168 mIU/L (7.92 μg/L) and the reference range is 71–348 mIU/L (3.35–16.4 μg/L). Hyperprolactinaemia, or excess serum prolactin, is associated with hypoestrogenism, anovulatory infertility, oligomenorrhoea, amenorrhoea, unexpected lactation and loss of libido in women and erectile dysfunction and loss of libido in men. Causes of Elevated Prolactin Levels
Alpha decay energy follows the same trend as for other heavy elements. The lighter astatine isotopes have quite high decay energies, which become lower as more neutrons are added, reaching a minimum at 125 neutrons (astatine-210), even though 126 (astatine-211) is the magic number. The decay energies increase much more steeply, though, on the next two steps, reaching a high at 128 neutrons where the alpha-decay product would have the magic number of 126. Here this is astatine-213, releasing the highest energy and having the shortest life (125 ns) of all the isotopes. The energy then declines again, and alpha lifetimes increase quickly, no long-lived astatine isotope exists; this happens due to the increasing role of beta decay. This decay mode is especially important for astatine: as early as 1950, it was postulated that the element has no beta-stable isotopes (i.e. ones that do not undergo beta decay at all), though nuclear mass measurements reveal that 215At is in fact beta-stable, as it has the lowest mass of all isobars with A = 215. A beta decay mode has been found for all other astatine isotopes except for 212-216At and their isomers. Among other isotopes, if they do not undergo alpha decay: astatine-210 and the lighter isotopes decay by electron capture or positron emission, 211 by electron capture only, and astatine-217 and heavier isotopes undergo β- decay. Astatine-212, 214, and 216 should be able to decay either way.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.